Scholarlink

Purpose <p>A long-acting exendin-4 (EX-ABD-AFF)-coated selenium nanoparticle (EX-ABD-AFF-SeNP) was synthesized, and its hypoglycemic activity was evaluated in vivo.</p> Methods <p>EX-ABD-AFF-SeNP was prepared by adopting a one-step aqueous reduction process. Its physical characteristics, stability, cytotoxicity, pharmacokinetics (PK), biodistribution, and preliminary efficacy were evaluated.</p> Results <p>The successful synthesis of EX-ABD-AFF-SeNP was confirmed through transmission electron microscopy, dynamic light scattering, ultraviolet–visible light spectroscopy, and Fourier transform infrared spectroscopy. The prepared EX-ABD-AFF-SeNP showed low cytotoxicity in different cell lines. Notably, the EX-ABD-AFF-SeNP showed long-lasting features in blood circulation with subcutaneous (s.c.) administration. The group treated with the EX-ABD-AFF-SeNP exhibited significant and superior hypoglycemic activity compared to the other groups. This hypoglycemic activity was demonstrated through measurements in high-fat diet mice, indicating its potential as an effective diabetes treatment.</p> Conclusion <p>The study's findings demonstrated that EX-ABD-AFF-SeNP might be an efficient therapeutic agent for diabetes treatment, potentially inspiring new avenues for diabetes research and treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-acting exendin-4-coated selenium nanoparticles with improved hypoglycemic activity

  • 期刊论文

  • 发表日期：

    2025年1月16日

查看全文
  • Reeju Amatya,
  • Amala Joseph,
  • Gu Seob Roh,
  • Kwan Hyung Cho,
  • Cheol Moon,
  • Kyoung Ah Min,
  • Meong Cheol Shin

摘要

Purpose

A long-acting exendin-4 (EX-ABD-AFF)-coated selenium nanoparticle (EX-ABD-AFF-SeNP) was synthesized, and its hypoglycemic activity was evaluated in vivo.

Methods

EX-ABD-AFF-SeNP was prepared by adopting a one-step aqueous reduction process. Its physical characteristics, stability, cytotoxicity, pharmacokinetics (PK), biodistribution, and preliminary efficacy were evaluated.

Results

The successful synthesis of EX-ABD-AFF-SeNP was confirmed through transmission electron microscopy, dynamic light scattering, ultraviolet–visible light spectroscopy, and Fourier transform infrared spectroscopy. The prepared EX-ABD-AFF-SeNP showed low cytotoxicity in different cell lines. Notably, the EX-ABD-AFF-SeNP showed long-lasting features in blood circulation with subcutaneous (s.c.) administration. The group treated with the EX-ABD-AFF-SeNP exhibited significant and superior hypoglycemic activity compared to the other groups. This hypoglycemic activity was demonstrated through measurements in high-fat diet mice, indicating its potential as an effective diabetes treatment.

Conclusion

The study's findings demonstrated that EX-ABD-AFF-SeNP might be an efficient therapeutic agent for diabetes treatment, potentially inspiring new avenues for diabetes research and treatment.